Pharmacotherapy of Respiratory Diseases in the Elderly

farmakoloji-11-2-2023-wos

İsmail Mert VURALa , İpek Kıvılcım OĞUZÜLGENb

aUniversity of Health Sciences Gülhane Faculty of Pharmacy, Department of Pharmacology, Ankara, Türkiye
bGazi University Faculty of Medicine, Department of Chest Diseases, Ankara, Türkiye

ABSTRACT
Asthma and chronic obstructive pulmonary disease (COPD) are the most prevalent chronic respiratory diseases. In the elderly population, they exhibit distinct yet significant patterns in terms of epidemiology, incidence rates, and characteristics. Bronchodilators such as beta-adrenergic receptor agonists, anticholinergic drugs, and phosphodiesterase inhibitors are used as mono or combined therapy in the treatment of various obstructive respiratory diseases. Inhaled corticosteroids are used for reducing bronchial hyperactivity and symptoms via reducing airway inflammation. Leukotriene receptor antagonists, phosphodiesterase-4 inhibitors, monoclonal antibodies, antitussive drugs, mucolytics and expectorants are the other drugs used in respiratory diseases. There’re many physiological changes that will affect the pharmacokinetics and pharmacodynamics of drugs used in the treatment of geriatric patients. Comorbidity, pathological changes, polypharmacy, and drug-drug interactions are the main factors that change the effects of drugs in elderly patients. Rational use of inhaled drug devices also is important for the success of treatment in the elderly.
Keywords: Respiratory tract diseases; geriatrics; bronchodilator agents

Referanslar

  1. Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric Pharmacology: An Update. Anesthesiol Clin. 2019;37(3):475-92. [Crossref]  [PubMed]
  2. Wallin M, Tagami T, Chen L, Yang M, Chan HK. Pulmonary drug delivery to older people. Adv Drug Deliv Rev. 2018:50-61. [Crossref]  [PubMed]
  3. Astım Tanı ve Tedavi Rehberi Astımın Kronik Tedavisi Basamak Tedavisi 2022 Güncellemesi. Ed: Çelik G, Aydın Ö. Aralık 2022. ISBN: 978-605-74980-9-0. BULUŞ Tasarım ve Matbaacılık Hizmetleri San. Tic., Ankara. Available from: [Link]
  4. Türk Toraks Derneği KOAH Çalışma Grubu'nun GOLD 2023 Güncellemesine Bakışı. Polatlı M, Baha A, Gürgün A, Özgen Alpaydın A, Şen E, Polat Yuluğ D, ve ark., editörler. BULUŞ Tasarım ve Matbaacılık Hizmetleri; 2023. Erişim linki: [Link]
  5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. GINA; 2023. Available from: www.ginasthma.org/reports.
  6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis, and Management of COPD: 2023 Report. [Link]
  7. Bayar B, Kutkan NU, Şafak Yılmaz E, Tolun Ç, Doğan E, Atikeler EK, et al. Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases: 1998--2015 Period in Turkey. Value Health Reg Issues. 2017;13:31-8. [Crossref]  [PubMed]
  8. Turan O, Turan PA, Mirici A. Parameters affecting inhalation therapy adherence in elderly patients with chronic obstructive lung disease and asthma. Geriatr Gerontol Int. 2017;17(6):999-1005. [Crossref]  [PubMed]
  9. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010;376(9743):803-13. [Crossref]  [PubMed]
  10. Wendell SG, Fan H, Zhang C. G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. Pharmacol Rev. 2020;72(1):1-49. [Crossref]  [PubMed]
  11. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res. 2003;4:4. [Crossref]
  12. Billington CK, Ojo OO, Penn RB, Ito S. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther. 2013;26(1):112-20. [Crossref]  [PubMed]
  13. Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in Elderly workshop participants. Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4-24. [Crossref]  [PubMed]
  14. Korsgaard J, Ledet M. Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists. Respir Med. 2009;103(4):566-73. [Crossref]  [PubMed]
  15. Bozkurt TE. Solunum Sistemi İlaçlarının Toksik Etkileri. Erdem O, Bacanlı M, Vural IM, editörler. Farmasötik Toksikoloji. 1. Baskı. Ankara: Ankara Nobel Yakini; 2022. p. 237-48.
  16. Akgün KM, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012;67(3):276-91. [Crossref]  [PubMed]
  17. Chotirmall SH, Watts M, Branagan P, Donegan CF, Moore A, McElvaney NG. Diagnosis and management of asthma in older adults. J Am Geriatr Soc. 2009;57(5):901-9. [Crossref]  [PubMed]
  18. Soler X, Ramsdell J. Anticholinergics/antimuscarinic drugs in asthma. Curr Allergy Asthma Rep. 2014;14(12):484. [Crossref]  [PubMed]
  19. Williams DM, Rubin BK. Clinical Pharmacology of Bronchodilator Medications. Respir Care. 2018;63(6):641-54. [Crossref]  [PubMed]
  20. Tilley SL. Methylxanthines in asthma. Handb Exp Pharmacol. 2011;(200):439-56. [Crossref]  [PubMed]
  21. Irazuzta JE, Chiriboga N. Magnesium sulfate infusion for acute asthma in the emergency department. J Pediatr (Rio J). 2017;93 Suppl 1:19-25. [Crossref]  [PubMed]
  22. Rowe BH, Camargo CA Jr. The role of magnesium sulfate in the acute and chronic management of asthma. Curr Opin Pulm Med. 2008;14(1):70-6. [Crossref]  [PubMed]
  23. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017;70(2):128-34. [Crossref]  [PubMed]
  24. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042-50. [Crossref]  [PubMed]
  25. Miravitlles M, Auladell-Rispau A, Monteagudo M, Vázquez-Niebla JC, Mohammed J, Nuñez A, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075. [Crossref]  [PubMed]
  26. D'Urzo AD, Chapman KR. Leukotriene-receptor antagonists. Role in asthma management. Can Fam Physician. 2000;46:872-9.
  27. Dixon EG, Rugg-Gunn CE, Sellick V, et al. Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic reviewBMJ Paediatrics Open 2021;5:e001206. [Crossref]  [PubMed]
  28. Kawamatawong T. Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases. Front Pharmacol. 2021;12:518345. [Crossref]  [PubMed]
  29. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;9(9): CD002309. [Crossref]
  30. Narváez-Fernández EJ, Entrala A , Nin-Valencia A, Mir-Ihara P, Losantos-García I, Domínguez-Ortega J, et al. Long-Term Omalizumab in Elderly Patients with Chronic Urticaria: Is It a Safe Therapy? Int Arch Allergy Immunol. 2023;1-7. [Crossref]  [PubMed]